Silencing of hPEBP4 sensitizes the cancer cells to TNF-α/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by increasing activation of JNK (c-Jun N-terminal kinase) and the Raf-1/MEK/ERK pathway, indicating that hPEBP4 is a candidate target molecule [14]–[17]. Here, TNFSF10 is linked to cancer.